Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Elzasonan

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Elzasonan
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one
CAS Number
PubChemCID
ChemSpider
UNII
Chemical and physical data
FormulaC22H23Cl2N3OS
Molar mass448.41 g·mol−1
3D model (JSmol)
  • Clc4c(Cl)cc(N1C(=O)C(\SCC1)=C\c3ccccc3N2CCN(C)CC2)cc4
  • InChI=1S/C22H23Cl2N3OS/c1-25-8-10-26(11-9-25)20-5-3-2-4-16(20)14-21-22(28)27(12-13-29-21)17-6-7-18(23)19(24)15-17/h2-7,14-15H,8-13H2,1H3/b21-14-
  • Key:LHYMPSWMHXUWSK-STZFKDTASA-N
  (verify)

Elzasonan (CP-448,187) is aselective5-HT1B and5-HT1D receptorantagonist that was under development byPfizer for the treatment ofdepression but was discontinued, possibly due to poor efficacy.[1][2][3][4][5] By preferentially blocking 5-HT1B and 5-HT1Dautoreceptors, elzasonan is thought to enhanceserotonergic innervations originating from theraphe nucleus, thereby improving signaling tolimbic regions like thehippocampus andprefrontal cortex and ultimately resulting inantidepressant effects.[3]

See also

[edit]

References

[edit]
  1. ^Vela JM, Buschmann H, Holenz J, Párraga A, Torrens A (2007).Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH.ISBN 978-3-527-31058-6.
  2. ^Stahl SM (2008).Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge, UK: Cambridge University Press.ISBN 978-0-521-85702-4.
  3. ^abDawson LA, Bromidge SM (August 2008). "5-HT1 receptor augmentation strategies as enhanced efficacy: therapeutics for psychiatric disorders".Current Topics in Medicinal Chemistry.8 (12):1008–1023.doi:10.2174/156802608785161439.PMID 18691129.
  4. ^Norman P (2002). "Pfizer, Inc.: analysis of patenting 1998 – 2001".Expert Opinion on Therapeutic Patents.12 (5):725–732.doi:10.1517/13543776.12.5.725.S2CID 84645020.
  5. ^Kirchhoff VD, Nguyen HT, Soczynska JK, Woldeyohannes H, McIntyre RS (October 2009). "Discontinued psychiatric drugs in 2008".Expert Opinion on Investigational Drugs.18 (10):1431–1443.doi:10.1517/13543780903184591.PMID 19715445.S2CID 34201544.
SSRIsTooltip Selective serotonin reuptake inhibitors
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors
NRIsTooltip Norepinephrine reuptake inhibitors
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants
SARIsTooltip Serotonin antagonist and reuptake inhibitors
SMSTooltip Serotonin modulator and stimulators
Others
TCAsTooltip Tricyclic antidepressants
TeCAsTooltip Tetracyclic antidepressants
Others
Non-selective
MAOATooltip Monoamine oxidase A-selective
MAOBTooltip Monoamine oxidase B-selective
Miscellaneous
5-HT1ARTooltip 5-HT1A receptoragonists
GABAARTooltip GABAA receptorPAMsTooltip positive allosteric modulators
Gabapentinoids
(α2δVDCCblockers)
Antidepressants
Sympatholytics
(Antiadrenergics)
Others
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Retrieved from "https://en.wikipedia.org/w/index.php?title=Elzasonan&oldid=1278786067"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp